You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 1
  • 4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment

Citation Tools

Article menu

Download PDFPDF

Section 4: Clinical pharmacy services
4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Macía-Rivas L, Fernández-Laguna C, Álvarez-Manceñido F, et al
4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment
European Journal of Hospital Pharmacy 2023;30:A96-A97.